Conference Coverage

Avoiding in-hospital acute kidney injury is a new imperative


 

EXPERT ANALYSIS FROM ACP INTERNAL MECICINE


“These are highly toxic drugs to the kidney and we shouldn’t be using them,” Dr. Szerlip said.

He reported receiving research grants from LaJolla, Bayer, Akebia, and BioPorto, serving on a speakers’ bureau for Astute Medical, and acting as a consultant to Zs Pharma, Amarin, and LaJolla.

Pages

Next Article:

   Comments ()